Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ESMO 2026

European Society For Medical Oncology

July 1-4, 2026

  1. All
  2. Trastuzumab deruxtecan
  3. Sonesitatug vedotin
  4. Durvalumab

PDF

Trastuzumab deruxtecan in Western patients with HER2-positive advanced gastric or gastroesophageal junction cancer who progressed on or after a trastuzumab-containing regimen: Final analysis of DESTINY-Gastric02, a single-arm, phase 2 trial

PDF

Real-world effectiveness and safety of trastuzumab deruxtecan in patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma: A multicenter prospective study in China (RECOVER Study)

PDF

CLDN18.2 dynamics and pharmacodynamic evaluation in patients with advanced/metastatic gastric cancer treated with sonesitatug vedotin in the CLARITY-PanTumor01 study

PDF

Immune-mediated adverse events (imAEs) in MATTERHORN: a Phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G / GEJ) adenocarcinoma

PDF

Immune-mediated adverse events (imAEs) in MATTERHORN: a Phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G / GEJ) adenocarcinoma [Suppl]

PDF

Real-World Treatment Patterns in Resectable Gastric and Gastroesophageal Junction Cancer in Germany: A Chart Review Study

PDF

Treatment patterns of resectable gastric (GC) and gastroesophageal junction cancer (GEJC): A multi-country chart review study

PDF

Durvalumab-Sangro B, et al. Overall survival (OS) in EMERALD-1: a Phase 3 study of durvalumab (D) ± bevacizumab (B) and transarterial chemoembolisation (TACE) in participants (pts) with unresectable embolisation-eligible hepatocellular carcinoma (eeHCC).

PDF

Tumour response analyses by RECIST v1.1 and mRECIST in the Phase 3 EMERALD-3 study of tremelimumab plus durvalumab with or without lenvatinib plus transarterial chemoembolisation in embolisation-eligible hepatocellular carcinoma​

PDF

Durvalumab (D) and tremelimumab (T) as first-line treatment (tx) for participants (pts) with unresectable hepatocellular carcinoma (uHCC) and a poor prognosis: primary efficacy and safety results from the Phase 3B SIERRA study

PDF

Safety and efficacy of durvalumab plus gemcitabine (gem)-based chemotherapy (chemo) regimens in participants (pts) with advanced biliary tract cancer (aBTC): Primary results from the Phase 3b TOURMALINE study

PDF

Safety and efficacy of durvalumab plus gemcitabine (gem)-based chemotherapy (chemo) regimens in participants (pts) with advanced biliary tract cancer (aBTC): Primary results from the Phase 3b TOURMALINE study [Suppl]

PDF

Real-world treatment (tx) outcomes of durvalumab (D)-based regimens in advanced biliary tract cancer (aBTC): LIVER-R interim analysis (IA)

PDF

Trastuzumab deruxtecan in Western patients with HER2-positive advanced gastric or gastroesophageal junction cancer who progressed on or after a trastuzumab-containing regimen: Final analysis of DESTINY-Gastric02, a single-arm, phase 2 trial

PDF

Real-world effectiveness and safety of trastuzumab deruxtecan in patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma: A multicenter prospective study in China (RECOVER Study)

PDF

CLDN18.2 dynamics and pharmacodynamic evaluation in patients with advanced/metastatic gastric cancer treated with sonesitatug vedotin in the CLARITY-PanTumor01 study

PDF

Immune-mediated adverse events (imAEs) in MATTERHORN: a Phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G / GEJ) adenocarcinoma

PDF

Immune-mediated adverse events (imAEs) in MATTERHORN: a Phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G / GEJ) adenocarcinoma [Suppl]

PDF

Real-World Treatment Patterns in Resectable Gastric and Gastroesophageal Junction Cancer in Germany: A Chart Review Study

PDF

Treatment patterns of resectable gastric (GC) and gastroesophageal junction cancer (GEJC): A multi-country chart review study

PDF

Durvalumab-Sangro B, et al. Overall survival (OS) in EMERALD-1: a Phase 3 study of durvalumab (D) ± bevacizumab (B) and transarterial chemoembolisation (TACE) in participants (pts) with unresectable embolisation-eligible hepatocellular carcinoma (eeHCC).

PDF

Tumour response analyses by RECIST v1.1 and mRECIST in the Phase 3 EMERALD-3 study of tremelimumab plus durvalumab with or without lenvatinib plus transarterial chemoembolisation in embolisation-eligible hepatocellular carcinoma​

PDF

Durvalumab (D) and tremelimumab (T) as first-line treatment (tx) for participants (pts) with unresectable hepatocellular carcinoma (uHCC) and a poor prognosis: primary efficacy and safety results from the Phase 3B SIERRA study

PDF

Safety and efficacy of durvalumab plus gemcitabine (gem)-based chemotherapy (chemo) regimens in participants (pts) with advanced biliary tract cancer (aBTC): Primary results from the Phase 3b TOURMALINE study

PDF

Safety and efficacy of durvalumab plus gemcitabine (gem)-based chemotherapy (chemo) regimens in participants (pts) with advanced biliary tract cancer (aBTC): Primary results from the Phase 3b TOURMALINE study [Suppl]

PDF

Real-world treatment (tx) outcomes of durvalumab (D)-based regimens in advanced biliary tract cancer (aBTC): LIVER-R interim analysis (IA)

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States